

PRIOR AUTHORIZATION REQUEST FORM
XHANCE®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight: _____

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred: fluticasone propionate nasal spray, mometasone nasal spray

Non-preferred: Xhance® (fluticasone propionate)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Does the member have a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) confirmed by one of the following? <ul style="list-style-type: none"> • Anterior rhinoscopy • Nasal endoscopy • Computed tomography (CT) 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the request being made by or in consultation with an allergist, ENT specialist, or pulmonologist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Is the member at 18 years of age or older?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Does documentation show a 3 month trial and failure of or contraindication/intolerance to BOTH of the following intranasal steroids? <ul style="list-style-type: none"> • fluticasone propionate 50 mcg/actuation nasal spray • mometasone furoate 50 mcg/actuation nasal spray 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

REAUTHORIZATION

1. Is the requesting for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member's therapy been re-evaluated within the past 6 months?	<input type="checkbox"/>	<input type="checkbox"/>	

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

3. Has the therapy shown to be effective with an improvement in condition?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the member show a continued medical need for the therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

PHARM- 086

Origination Date: 10/28/2019

Reviewed/Revised Date: 10/28/2020

Next Review Date: 10/28/2021

Current Effective Date: 11/01/2020

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.